YURTAYDIN, S. C. Et Al. 2017. A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study. International Liver Congress 2017 .

YURTAYDIN, S. C., İDİLMAN, R., KESKİN, O., KALKAN, Ç., KARAKAYA, M. F., ÇALIŞKAN KARTAL, A., ... Yurdcu, E.(2017). A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study . International Liver Congress 2017

YURTAYDIN, SÜLEYMAN Et Al. "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study," International Liver Congress 2017, 2017

YURTAYDIN, SÜLEYMAN C. Et Al. "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study." International Liver Congress 2017 , 2017

YURTAYDIN, S. C. Et Al. (2017) . "A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study." International Liver Congress 2017 .

@conferencepaper{conferencepaper, author={SÜLEYMAN CİHAN YURTAYDIN Et Al. }, title={A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study}, congress name={International Liver Congress 2017}, city={}, country={}, year={2017}}